fda bpc 157 category 2 compounding Peptide Review 2026: What This Big Shift Means Category 1 vs. Category 2.
Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means You may have heard buzz about 14 peptides potentially returning to legal compounding. Here's what we know: HHS Secretary RFK Jr. stated his intention to move these peptides from FDA Category 2 This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the FDA will make BPC 157 FDA Approval Status 2026: Clinical Trials 83% of peptide aware Americans want the FDA to make peptides more accessible AOL Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law
Pay in 4 interest-free payments of $5.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10


